NCT05974969View on ClinicalTrials.gov

A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions
Healthy
Interventions
DRUG

BCD-264

a single intravenous infusion of BCD-264

DRUG

Darzalex

a single intravenous infusion of Darzalex

Trial Locations (3)

Unknown

Institute of the Human Brain n. a. N.P. Bekhtereva Russian Academy of Sciences, Saint Petersburg

Smorodintsev Research Institute of Influenza, Saint Petersburg

X7 Clinical Research, Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT05974969 - A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects | Biotech Hunter | Biotech Hunter